EUVIMEDEUVIMED entdecken
Crossref

Development and Mechanistic Evaluation of Cathepsin B‐Activatable Peptide‐Drug Conjugate PROTACs for Targeted Protein Degradation in Malignant Tumors: Advancing Precision Protein Degradation Therapeutics in Oncology

Qingqing Zhang, Yu Liu, Jie Zhang, Hengtao Dong, Xiaoyan Pan iD, Jie Zhang

Small · 2026-01 · 22 (4)

DOI: 10.1002/smll.202506562 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, online erschienen am 12.12.2025. Verfasst von Qingqing Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, 710061, China. Hauptthemen laut MEDLINE: Cathepsin B, Proteolysis, Neoplasms, Peptides. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shaanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the advent of proteolysis targeting chimeras (PROTACs), both small molecule PROTACs and peptide‐based PROTACs have exhibited distinct advantages. However, PROTACs still exist issues such as poor membrane permeability, low bioavailability, and potential off‐target effects. The development of novel PROTACs represents an innovative approach to addressing these challenges. Here, a class of novel PDC‐PROTACs is designed and modified with cell‐penetrating peptides and tumor‐targeting peptides, which incorporate a Cathepsin B‐sensitive sequence to enhance the targeting of PROTACs to tumor cells and ensure their controlled release within these cells. Subsequent verification employing HPLC‐MRM‐MS technology confirms that the utilization of functional peptides and enzyme‐sensitive linkers significantly augments the intracellular concentration of PDC‐PROTACs, demonstrating improved transmembrane delivery efficiency. Compared to HIF‐S or HIF‐IMA , the enzyme‐responsive PDC‐PROTACs Cyclo‐A7R‐RRR‐GFLG‐HIF‐S and Cyclo‐C9C‐R‐GFLG‐HIF‐IMA demonstrate enhanced anti‐proliferation activity, target protein degradation, and pro‐apoptotic effects. In vivo studies indicate that Cyclo‐A7R‐RRR‐GFLG‐HIF‐S exhibits favorable therapeutic efficacy and safety profile in the U87MG xenograft mouse model. In summary, this research culminates in the creation of novel enzyme‐responsive PDC‐PROTACs, which leverage the elevated expression of specific enzymes in tumor cells to promote their release, thus enabling the degradation of target proteins. The innovative enzyme‐responsive PDC‐PROTACs hold considerable promise for tumor therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cathepsin BProteolysisNeoplasmsPeptidesHumansAnimalsCell Line, TumorMiceMice, NudeAntineoplastic AgentsProteolysis Targeting Chimera

Stichwörter der Autor:innen

antitumorcancer targeted penetrating peptide (CTP)enzyme‐responsivepeptide‐drug conjugate (PDC)proteolysis targeting chimera (PROTAC)

Substanzen

Cathepsin BPeptidesAntineoplastic AgentsProteolysis Targeting Chimera

Autor:innen und Institutionen

  • School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, 710061, China.
  • Department of Tumor and Immunology in Precision Medical Institute and Western China Science and Technology Innovation Port, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, China.
  • Analytical Application Center, Shimadzu (China) Co.,Ltd., Xi'an, 710075, China.

ORCID-Profile: Xiaoyan Pan

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Shaanxi Province

Zitieren

APA

Zhang, Q., Liu, Y., Zhang, J., Dong, H., Pan, X., & Zhang, J. (2026). Development and Mechanistic Evaluation of Cathepsin B‐Activatable Peptide‐Drug Conjugate PROTACs for Targeted Protein Degradation in Malignant Tumors: Advancing Precision Protein Degradation Therapeutics in Oncology. Small, 22(4). https://doi.org/10.1002/smll.202506562

Vancouver

Zhang Q, Liu Y, Zhang J, Dong H, Pan X, Zhang J. Development and Mechanistic Evaluation of Cathepsin B‐Activatable Peptide‐Drug Conjugate PROTACs for Targeted Protein Degradation in Malignant Tumors: Advancing Precision Protein Degradation Therapeutics in Oncology. Small. 2026;22(4). doi:10.1002/smll.202506562

BibTeX
@article{Zhang2026,
  author = {Zhang, Qingqing and Liu, Yu and Zhang, Jie and Dong, Hengtao and Pan, Xiaoyan and Zhang, Jie},
  title = {Development and Mechanistic Evaluation of Cathepsin B‐Activatable Peptide‐Drug Conjugate PROTACs for Targeted Protein Degradation in Malignant Tumors: Advancing Precision Protein Degradation Therapeutics in Oncology},
  journal = {Small},
  year = {2026},
  volume = {22},
  number = {4},
  doi = {10.1002/smll.202506562}
}
Kostenlos starten →